In vivo studies of NBL
| Tumor size (cm3) | Analysis of slopea | ||||||
|---|---|---|---|---|---|---|---|
| Cell line | Day of analysis | Compound | Control | Compound | Control | ||
| A. Neuroblastoma therapeutic studiesb | |||||||
| IMR-5 | 12 | 1.96 ± 0.35 (n = 5) | 3.91 ± 1.22 (n = 5) | 0.17 ± 0.051 (n = 5) | 0.28 ± 0.109 (n = 5) | ||
| P = 0.025 | P = 0.024 | ||||||
| CHP 134 | 15 | 1.9 ± 0.75 (n = 4) | 4.5 ± 0.98 (n = 3) | 0.151 ± 0.055 (n = 6) | 0.299 ± 0.068 (n = 5) | ||
| P = 0.034 | P = 0.12 | ||||||
| NBL-S | 17 | 0.94 ± 0.24 (n = 5) | 5.2 ± 2.46 (n = 4) | 0.15 ± 0.034 (n = 5) | 0.264 ± 0.014 (n = 4) | ||
| P = 0.016 | P = 0.12 | ||||||
| B. Neuroblastoma prevention studiesc | |||||||
| IMR-5 | 27 | 1.3 ± 1.63 (n = 7) | 2.7 ± 1.55 (n = 6) | 0.118 ± 0.036 (n = 7) | 0.188 ± 0.041 (n = 6) | ||
| P = 0.062 | P = 0.073 | ||||||
| CHP 134 (combined) | See text | 0.064 ± (n = 6) | 0.122 ± (n = 6) | ||||
| P = 0.058 | |||||||
| CHP 134 (early) | 29 | See text | 0.148 ± 0.013 (n = 3) | 0.169 ± 0.01 (n = 3) | |||
| P = 0.28 | |||||||
| CHP 134 (late) | 58 | See text | 0.022 ± 0.011 (n = 3) | 0.140 ± 0.009 (n = 3) | |||
| P = 0.049 | |||||||
a Figures given for the average daily growth rate.
b Treatment started after tumors measured >0.24 g.
c Treatment commenced prior to tumor appearance.